Company / R&D Expense
PULSE BIOSCIENCES, INC. R&D Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$44.7M
FY2025
5-year range
$20.8M / $44.7M
FY2021-FY2025
Trend
+38.3%
vs FY2024
Sector context
#84 of 110
Health Care
What the data says
PULSE BIOSCIENCES, INC.'s r&d expense of $45M is lower than 76% of companies in the Health Care sector (FY2025). Improved from $21M to $45M over the past 2 years.
Based on SEC 10-K filings.
$45M in FY2025 with a 5-year CAGR of +11.1%.
Improved from $21M to $45M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +29.0%
- 5-Year CAGR
- +11.1%
- 10-Year CAGR
- -
Sector benchmark
Bottom 24% in Health CareTop 76% of 110This company $44.7M Sector average $298.2M
▼
-85.0% below sector average
Key checks
Key Insights
- 5-year CAGR of +11.1%, indicating consistent growth.
- In FY2025, r&d expense increased 38.3% year-over-year.
- Ranks #84 out of 110 companies in the Health Care sector.
- Lowest r&d expense in the period was in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -3.66 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $44.7M | +38.3% |
| FY2024 | $32.3M | +55.2% |
| FY2023 | $20.8M | +0.0% |
| FY2022 | $20.8M | -27.2% |
| FY2021 | $28.6M | +8.3% |
| FY2020 | $26.4M | +5.9% |
| FY2019 | $25.0M | +44.7% |
| FY2018 | $17.3M | +78.9% |
| FY2017 | $9.6M | +75.2% |
| FY2016 | $5.5M | +152.5% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026